Dr. Mehta has a track record of delivering high-quality research outcomes in a range of settings. Selected examples of his research activity include:
2026 – ongoing Chief Investigator, NutriOpen-IBD study
Nutrition substudy prospectively measuring nutritional parameters in participants with newly diagnosed IBD and control participants recruited to the UK Open-IBD study (Open-IBD funded via Open Targets; £11.3m)
2026 – ongoing Principal Investigator, EASE study
2026 – ongoing Principal Investigator, Oral health and behaviours of adults with chronic intestinal failure requiring home parenteral nutrition.
ESPEN Chronic Intestinal Failure Special Interest Group (SIG)-endorsed study
2025 – 2028 Chair, BAPEN Medical Clinical Research Group
2024 – ongoing Chief Investigator, NUTRICO-IBD study
Prospective study of nutritional markers in patients with IBD undergoing advanced medical therapy or surgery
2024 – ongoing Principal Investigator, EFFECT-UC study
2023 – ongoing Principal Investigator, STARS trial
2023 – ongoing Principal Investigator, THAMES-IBD study
2023 – ongoing Principal Investigator, Colo-cohort study
2020 – 2022 Principal Investigator and Study Management Group member, CLARITY-IBD study
2020 – 2022 Principal Investigator and Study Management Group member, PREPARE-IBD study
2020 Principal Investigator, UK study of COVID-19 infection rates and outcomes in patients with chronic intestinal failure
2019 – 2023 Chief Investigator, IFALD-UK
UK study of clinical characteristics, prognostic indicators and histological reporting standards in patients with intestinal failure-associated liver disease
2012 – 2015 MD(Res) Research Fellow, Blizard Institute, QMUL
2000 BSc Molecular Medicine Research Project, The Rayne Institute, St Thomas’ Hospital